Core Insights - Fountain Life has established a strategic partnership with Celularity to supply stem cell therapy products, leveraging new Florida legislation that allows licensed physicians to administer these therapies without FDA investigational new drug approval [1][2][5] Company Overview - Fountain Life operates four longevity centers in the U.S., including locations in Naples and Lake Nona-Orlando, Florida, with plans to open a new center in Miami [3] - Celularity specializes in regenerative and cellular medicine, focusing on therapies derived from the postpartum placenta, and maintains a substantial inventory of investigational cell therapies at its GMP facility in New Jersey [4][7] Regulatory Framework - The new Florida law, effective July 1, 2025, permits qualified physicians to treat patients with autologous or allogeneic adult stem cell products for specific conditions, including orthopedic issues, wound healing, and pain management [2] - This regulatory change provides a framework for the real-world application of Celularity's placental-based technologies [5] Strategic Alignment - The partnership aligns with Celularity's mission to enhance access to regenerative therapies and supports Fountain Life's commitment to high standards in safety, efficacy, and scalability of regenerative treatments [5][6] - Both companies emphasize a data-driven approach to healthcare, with Fountain Life utilizing advanced AI diagnostics and therapeutics to promote longevity [10]